Overview

Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis Suppurativa

Status:
Not yet recruiting

Trial end date:
2022-10-01

Target enrollment:

Participant gender:

Summary

A 16 week exploratory, Proof of Concept study to evaluate the effect of Fostamatinib (12 weeks of treatment) upon cutaneous inflammation in Hidradenitis Suppurativa.

Phase:

Phase 2

Details

Lead Sponsor:

Holdsworth House Medical Practice

Collaborator:

Rigel Pharmaceuticals